[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,662
  • Shares Outstanding, K 84,614
  • Annual Sales, $ 1,410 K
  • Annual Income, $ -62,420 K
  • EBIT $ -67 M
  • EBITDA $ -67 M
  • 60-Month Beta 0.18
  • Price/Sales 17.98
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.95
  • Most Recent Earnings $-0.22 on 02/17/26
  • Next Earnings Date 05/21/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 399.90% (+113.32%)
  • Historical Volatility 195.15%
  • IV Percentile 90%
  • IV Rank 43.12%
  • IV High 818.65% on 02/27/26
  • IV Low 82.45% on 02/06/26
  • Expected Move (DTE 18) 0.1785 (61.38%)
  • Put/Call Vol Ratio 3.41
  • Today's Volume 203
  • Volume Avg (30-Day) 688
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 19,415
  • Open Int (30-Day) 17,148
  • Expected Range 0.1123 to 0.4693

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 3
  • High Estimate $-0.07
  • Low Estimate $-0.15
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) +70.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1800 +61.33%
on 04/07/26
0.3930 -26.11%
on 04/21/26
+0.0823 (+39.55%)
since 03/27/26
3-Month
0.1611 +80.26%
on 03/24/26
0.5250 -44.69%
on 02/13/26
-0.2068 (-41.59%)
since 01/27/26
52-Week
0.1611 +80.26%
on 03/24/26
3.3900 -91.43%
on 08/26/25
-1.2396 (-81.02%)
since 04/25/25

Most Recent Stories

More News
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard...

OTLK : 0.2886 (-8.41%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard...

OTLK : 0.2886 (-8.41%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2886 (-8.41%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2886 (-8.41%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2886 (-8.41%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2886 (-8.41%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Proposed Public Offering

ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2886 (-8.41%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2886 (-8.41%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2886 (-8.41%)
OTLKW : 0.03 (-1.96%)

Business Summary

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as...

See More

Key Turning Points

3rd Resistance Point 0.3699
2nd Resistance Point 0.3450
1st Resistance Point 0.3300
Last Price 0.2886
1st Support Level 0.2901
2nd Support Level 0.2652
3rd Support Level 0.2502

See More

52-Week High 3.3900
Fibonacci 61.8% 2.1566
Fibonacci 50% 1.7756
Fibonacci 38.2% 1.3945
Last Price 0.2886
52-Week Low 0.1611

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.